Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
RESEARCH TOOLSreports
PRAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.70 - $91.83
Previous CloseN/A
Volume51.58K
Average Volume (3M)681.46K
Market Cap
$574.05M
Enterprise Value$1.15B
Total Cash (Recent Filing)-$17.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.40
Next Earnings
May 07, 2025EPS Estimate
-3.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.27
Shares Outstanding20,163,250
10 Day Avg. Volume690,744
30 Day Avg. Volume681,461
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)87.51
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap2.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit468.52
Enterprise Value/Ebitda-7.00
Forecast
1Y Price Target
$119.50Price Target Upside319.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Praxis Precision Medicines News
PremiumCompany Announcements
Praxis Precision Medicines Updates on Programs and Finances
---
Bulls Say, Bears Say
Bulls Say
Epilepsy PortfolioThe company remains well positioned to drive meaningful shareholder value from its epilepsy portfolio.
Financial StabilityCash of $469.5M provides financial stability and runway to 2028.
Bears Say
Earnings PerformanceEarnings per share came in below both analyst and Street estimates due to increasing R&D costs.
Study FutilityThe IDMC recommended stopping Study 1 for futility, impacting the valuation of PRAX.
---
Ownership Overview
10.85% Insiders
19.33% Mutual Funds
3.00% Other Institutional Investors
53.17% Public Companies and
Individual Investors
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $26.70 and its highest was $91.83 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $574.05M.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is May 07, 2025 which is in 25 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Feb 28, 2025. The company reported -$2.94 earnings per share for the quarter, missing the consensus estimate of -$2.847 by -$0.093.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -3.2.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 20,163,250 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$2.94 in its last earnings report, missing expectations of -$2.847. Following the earnings report the stock price went down -40.643%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Currently, no hedge funds are holding shares in PRAX
---
Praxis Precision Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$119.50 (319.74% Upside)
$119.50 (319.74% Upside)
Blogger Sentiment
Neutral
PRAX Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 175.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.74%
12-Months-Change
Fundamentals
Return on Equity
-70.98%
Trailing 12-Months
Asset Growth
449.31%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
---
PRAX Stock 12 Month Forecast
Average Price Target
$119.50
▲(319.74% Upside)
Technical Analysis
Gyre Therapeutics
―
Xencor
―
Intellia Therapeutics
―
Xeris Pharmaceuticals
―
Nuvation Bio
―
Best Analysts Covering PRAX
1 Year
1 Year Success Rate
11/27 ratings generated profit
1 Year Average Return
+57.61%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 40.74% of your transactions generating a profit, with an average return of +57.61% per trade.
---